- Home
- SYRE vs ATRC Comparison
SYRE vs ATRC Comparison
Compare SYRE & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- ATRC
- Stock Information
- Founded
- SYRE 2013
- ATRC 2000
- Country
- SYRE United States
- ATRC United States
- Employees
- SYRE 60
- ATRC N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- ATRC Medical/Dental Instruments
- Sector
- SYRE Health Care
- ATRC Health Care
- Exchange
- SYRE Nasdaq
- ATRC Nasdaq
- Market Cap
- SYRE 1.3B
- ATRC 1.1B
- IPO Year
- SYRE 2016
- ATRC 2005
- Fundamental
- Price
- SYRE $21.29
- ATRC $38.39
- Analyst Decision
- SYRE Strong Buy
- ATRC Strong Buy
- Analyst Count
- SYRE 8
- ATRC 10
- Target Price
- SYRE $51.50
- ATRC $49.50
- AVG Volume (30 Days)
- SYRE 550.7K
- ATRC 539.4K
- Earning Date
- SYRE 03-03-2025
- ATRC 02-12-2025
- Dividend Yield
- SYRE N/A
- ATRC N/A
- EPS Growth
- SYRE N/A
- ATRC N/A
- EPS
- SYRE N/A
- ATRC N/A
- Revenue
- SYRE N/A
- ATRC $465,307,000.00
- Revenue This Year
- SYRE $168.62
- ATRC $14.41
- Revenue Next Year
- SYRE $47.61
- ATRC $12.87
- P/E Ratio
- SYRE N/A
- ATRC N/A
- Revenue Growth
- SYRE N/A
- ATRC 16.55
- 52 Week Low
- SYRE $20.13
- ATRC $18.94
- 52 Week High
- SYRE $47.97
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- SYRE 40.66
- ATRC 47.41
- Support Level
- SYRE $21.61
- ATRC $37.72
- Resistance Level
- SYRE $23.04
- ATRC $42.68
- Average True Range (ATR)
- SYRE 1.43
- ATRC 1.78
- MACD
- SYRE -0.03
- ATRC -0.59
- Stochastic Oscillator
- SYRE 22.03
- ATRC 13.51
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.